Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue: +9.96%
EPS: +267.0%
Free cash flow: −50.9%
Total debt: +23.8%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

19.94 0.49 +2.52%

Follow AMRX

Alert me

Market cap: $6.8B
P/E: 36.9×
Fwd P/E: 44.2×
Dividend yield: —
F-score: 7/9
Altman Z: 1.94
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. (AMRX) Price to free cash flow

Alert me on Price to free cash flow

AMNEAL PHARMACEUTICALS, INC. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 40.9× (April 2019) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/AMRX/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="AMNEAL PHARMACEUTICALS, INC. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/AMRX/metrics/price-to-free-cash-flow">AMNEAL PHARMACEUTICALS, INC. (AMRX) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	17.3×	55.95%
FY2024	11.1×	191.73%
FY2023	3.8×	(43.60%)
FY2022	6.8×	321.02%
FY2021	1.6×	(25.49%)
FY2020	2.2×	—
FY2019	0.0×	—
FY2018	9.6×	(15.20%)
FY2017	11.4×	0.00%
FY2016	11.4×	0.00%

Period	Price to free cash flow	Change
Sep 2026	0.0×	—
Jun 2026	0.0×	—
Mar 2026	20.7×	19.45%
Dec 2025	17.3×	31.15%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 40.9×

Ten-year median 4.2×

Current reading's percentile 22

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC.	n/m
LNTH Lantheus Holdings, Inc. compare	16.9×
LQDA Liquidia Corporation compare	26.4×
ALKS Alkermes plc compare	32.8×
ELAN Elanco Animal Health Incorporated compare	33.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
SUPN Indivior Pharmaceuticals Inc. compare	115×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

AMNEAL PHARMACEUTICALS, INC. (AMRX) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on AMRX

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on AMRX

Stockrow Weekly